TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms

[1]  V. Rotter,et al.  Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis , 2023, Nature Communications.

[2]  Anna L. Brown,et al.  TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype. , 2022, Blood.

[3]  T. Haferlach,et al.  Interplay of TP53 Allelic State, Blast Count and Karyotype on Survival of Patients with AML and MDS , 2022, Blood.

[4]  J. Lancet,et al.  Characterization of TP53-Mutated Myelodysplastic Syndromes and Impact of Allelic Status and Concurrent Cytogenetic Abnormalities on Survival Outcomes , 2022, Blood.

[5]  Sharad Kumar,et al.  A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure , 2022, Leukemia.

[6]  A. Krasnitz,et al.  Ordered and deterministic cancer genome evolution after p53 loss , 2022, Nature.

[7]  A. Tefferi,et al.  Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms , 2022, Blood Cancer Journal.

[8]  M. Loh,et al.  International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. , 2022, Blood.

[9]  Y. Natkunam,et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms , 2022, Leukemia.

[10]  A. Wei,et al.  Outcomes following venetoclax‐based treatment in therapy‐related myeloid neoplasms , 2022, American journal of hematology.

[11]  Andrew T Nguyen,et al.  Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms , 2022, Blood.

[12]  K. Bhalla,et al.  TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia , 2022, Blood.

[13]  M. Jongen‐Lavrencic,et al.  Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome , 2022, Blood.

[14]  P. D. Dal Cin,et al.  TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML , 2022, Blood advances.

[15]  Benjamin L. Ebert,et al.  Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes , 2019, Nature Medicine.

[16]  M. Konopleva,et al.  Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. , 2020, Blood advances.

[17]  K. Pradhan,et al.  Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. , 2019, Blood advances.

[18]  Anna L. Brown,et al.  The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution , 2019, Leukemia.

[19]  C. Bloomfield,et al.  Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically , 2019, Leukemia.

[20]  P. Campbell,et al.  TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups , 2019, Leukemia.

[21]  J. Welch.  Patterns of mutations in TP53 mutated AML. , 2018, Best practice & research. Clinical haematology.

[22]  M. Konopleva,et al.  Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms , 2018, Oncotarget.

[23]  Megan E. McNerney,et al.  Therapy-related myeloid neoplasms: when genetics and environment collide , 2017, Nature Reviews Cancer.

[24]  D. Neuberg,et al.  Prognostic Mutations in Myelodysplastic Syndrome after Stem‐Cell Transplantation , 2017, The New England journal of medicine.

[25]  A. LaCasce,et al.  Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  W. Hiddemann,et al.  Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. , 2016, Blood.

[27]  J. Maciejewski,et al.  Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes , 2016, Leukemia.

[28]  J. Maciejewski,et al.  High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort , 2016, Leukemia.

[29]  S. Nahas,et al.  Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes , 2016, Leukemia.

[30]  M. Konopleva,et al.  Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents , 2016, Oncotarget.

[31]  B. Ko,et al.  TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution , 2015, Blood Cancer Journal.

[32]  Ken H. Young,et al.  Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. , 2015, Leukemia research.

[33]  Christopher A. Miller,et al.  The Role of TP53 Mutations in the Origin and Evolution of Therapy-Related AML , 2014, Nature.

[34]  C. Preudhomme,et al.  Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. , 2014, Leukemia research.

[35]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[36]  A. Stamatoullas,et al.  Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion , 2012, Genes, chromosomes & cancer.

[37]  C. Steidl,et al.  New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  S. Fröhling,et al.  TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. , 2012, Blood.

[39]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[40]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.